BAY 98-7106

BAY 98-7106 is a potent, selective, and orally bioavailable small molecule inhibitor of activated coagulation factor XI (FXIa), developed by Bayer for the prevention and treatment of thromboembolic disorders. By targeting FXIa, a key protease in the intrinsic pathway of the coagulation cascade, the drug aims to decouple the processes of pathological thrombosis and physiological hemostasis. This mechanism potentially offers a wider therapeutic window with a reduced risk of bleeding compared to conventional anticoagulants like warfarin or direct oral anticoagulants (DOACs) that inhibit Factor Xa or thrombin. Preclinical and early clinical evaluations focused on its pharmacokinetic profile and its ability to inhibit FXIa-mediated coagulation without significantly prolonging bleeding time. Although it was one of the first small molecule FXIa inhibitors to enter clinical development, it appears to have been superseded by subsequent candidates in Bayer's pipeline.